Monte Rosa Therapeutics, Inc. announced its second development candidate, MRT-6160, a novel, potent, and selective molecular glue degrader (MGD) of VAV1. The Company plans to file an Investigational New Drug (IND) application for MRT-6160 in the first half of 2024 and to develop the molecule as a potential treatment for autoimmune diseases.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
4.12 USD | -.--% | -0.96% | -27.08% |
May. 30 | Monte Rosa Therapeutics Names Three Insiders to Leadership Team | MT |
May. 30 | Monte Rosa Therapeutics, Inc. Announces Executive Promotions | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-27.08% | 252M | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- GLUE Stock
- News Monte Rosa Therapeutics, Inc.
- Monte Rosa Therapeutics Advances Second Development Candidate, MRT-6160, A Novel, Highly Selective Molecular Glue Degrader Targeting VAV1 for the Treatment of Autoimmune Diseases